Cytokinetics is a biopharmaceutical company that discovers, develops, and commercializes novel muscle activators and muscle inhibitors to treat diseases in which muscle performance is compromised or declining. The company's lead product is a cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy and other heart conditions, supported by a pipeline of investigational candidates in clinical development. The company generates revenue through product sales, license agreements and milestone payments from pharmaceutical partners, and collaboration arrangements, while funding operations through equity offerings, strategic alliances, and debt instruments.